Getinge announces date of 2013 Q2 report and conference call

        Print
| Source: Getinge AB
GETINGE will issue its Q2 report for 2013 on Thursday 11th of July 2013 at 08:30
CET, followed by a conference call at 10:00 CET, hosted by Johan Malmquist, CEO,
and Ulf Grunander, CFO.

We invite fund managers, analysts and the media to participate in the conference
call. Please see below details to join the conference:
Swedish dial in number: +46 (0) 8 5065 3937
UK dial in number: +44 (0) 20 3427 1910
Participant passcode: 5923551

Agenda
09:45 Call in to the conference
10:00 Review of the Q2 report
10:20 Q&A
11:00 End of conference

A recorded version of the conference can be accessed for 5 working days on the
following number:
Sweden: +46 (0) 8 5853 6965
UK: +44 (0) 20 3478 5300
US: +1 212 444 0412
Code: 5923551

During the telephone conference a presentation will be held. To access the
presentation, please use this link:

http://www.livemeeting.com/cc/premconfeurope/join?id=5923551&role=attend&pw=pw60
3 
4

Alternatively enter the VisionCast site and log into your meeting using the
Meeting ID and Password below:
VisionCast: http://www.euvisioncast.com
Your Name: (Enter your name)
Web Meeting ID: 5923551
Web Meeting Password: pw6034

For more information, please contact:
Kornelia Rasmussen
Group Communications
Phone: +46 (0)10 335 5810
E-mail: kornelia.rasmussen@getinge.com

GETINGE GROUP is a leading global provider of products and systems that
contribute to quality enhancement and cost efficiency within healthcare and life
sciences. We operate under the three brands of ArjoHuntleigh, GETINGE and
MAQUET. ArjoHuntleigh focuses on patient mobility and wound management
solutions. GETINGE provides solutions for infection control within healthcare
and contamination prevention within life sciences. MAQUET specializes in
solutions, therapies and products for surgical interventions, interventional
cardiology and intensive care.

The information is such that Getinge AB must disclose in accordance with the
Swedish Securities Market Act and/or the Financial Instruments Trading Act.